



BIOSENSORS
INTERNATIONAL™

NEWS RELEASE

Biosensors Receives CE Mark Approval for BioMatrix NeoFlex™

20 May 2013 – Biosensors International has announced CE Mark approval for BioMatrix NeoFlex™, the latest addition to the BioMatrix family of drug-eluting stents (DES).

BioMatrix NeoFlex features a new advanced stent delivery system, improving pushability, trackability and crossability. It also has a lower lesion entry profile than its predecessor. BioMatrix NeoFlex retains the same unique combination of abluminal biodegradable polymer coating, proprietary limus drug Biolimus A9™ (BA9™) and flexible platform which has made the BioMatrix stent family an increasingly popular choice of DES in the global markets where it is available.

The landmark LEADERS trial demonstrated the ‘Gold Standard’ performance of BioMatrix Flex™, and the baton has now been passed to the next generation in the form of BioMatrix NeoFlex, equipped with all the attributes of its successful predecessor, together with improved deliverability.

Results from the final five-year LEADERS data, presented at TCT 2012, demonstrated that BioMatrix Flex significantly reduced the risk of clinical events in the very late phase, and showed a significant reduction in very late stent thrombosis (VLST), compared with Cypher® Select™.

“CE Mark approval for BioMatrix NeoFlex represents another important step forward for the BioMatrix brand, improving our flagship product yet further with enhanced deliverability”, commented Jeffrey B. Jump, President of Biosensors’ Cardiovascular Division. “Since the launch of the original BioMatrix in 2008, we have been the driving force in biodegradable polymer stent technology: BioMatrix NeoFlex will enable us to retain this position.”

BioMatrix NeoFlex will be rolled out in all CE Mark global markets over the coming months.

###

For further information, please contact:

Corporate Communications
Richard Kenyon
Biosensors International Group
+44 7831 569940
r.kenyon@biosensors.com

Investor Relations
Wong Teck Yenn
Biosensors International Group
+65 6213 5708
ty.wong@biosensors.com

About Biosensors International Group, Ltd

Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the increasing use of the BioMatrix™ family of drug-eluting stents and the recent launch of our Axxess™ self-expanding bifurcation drug-eluting stent, we are rapidly emerging as a leader in the global coronary stent market. The development of the BioFreedom™ drug-coated stent will further reinforce our market position.

All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer-free stent abluminally coated with BA9, received CE Mark Approval in January 2013.

For more information, please visit www.biosensors.com